MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)。

Teriflunomide

CAS No. : 163451-81-8

產(chǎn)品活性：Teriflunomide is the active metabolite of leflunomide, an approved therapy for rheumatoid arthritis. It inhibits pyrimidine synthesis and therefore potently decreases T cell and B cell proliferation.

研究領(lǐng)域：Metabolic Enzyme/Protease

作用靶點：Drug Metabolite

In Vitro: Teriflunomide primarily acts as an inhibitor of dihydroorotate dehydrogenase (DHODH), a key mitochondrial enzyme involved in the de novo synthesis of pyrimidines in rapidly proliferating cells. By reducing the activity of high-avidity proliferating T lymphocytes and B lymphocytes, teriflunomide likely attenuates the inflammatory response to autoantigens in MS. Thus, teriflunomide can be considered a cytostatic rather than a cytotoxic drug to leukocytes.

In Vivo: Teriflunomide has demonstrated beneficial effects in two independent animal models of demyelinating disease. In the dark agouti rat model of experimental autoimmune encephalitis (EAE), teriflunomide administration results in clinical, histopathological, and electrophysiological evidence of efficacy both as a prophylactic and therapeutic agent. Similarly, in the female Lewis rat model of EAE, teriflunomide administration results in beneficial prophylactic and therapeutic clinical effects, with a delay in disease onset and symptom severity.

相關(guān)產(chǎn)品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Drug Metabolite Library  |  Rare Diseases Drug Library  |  EMA-Approved Drug Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  Off-patent Drug Library  |  Nicotinamide N-oxide  |  Cirsiliol 4′-glucoside  |  Desglymidodrine  |  4-Methylamino antipyrine hydrochloride  |  Tazarotenic acid-d₆  |  Trospium EP impurity C-d₈ (chloride)  |  Melamine  |  Febuxostat amide impurity  |  20-Carboxy-Leukotriene B4  |  O-Desmethyl Mebeverine acid-d₆  |  Desoxycarbadox  |  Ampyrone  |  Loxapine impurity 3-d₈ (iodide)  |  HMMNI-d₃  |  N-Desmethyl imatinib mesylate  |  Cidofovir diphosphate tri(triethylamine)  |  4-Hydroxymephenytoin-d₃  |  (Rac)-Nicotine EP impurity A-d₄ (hydrochloride)  |  Tetrachlorocatechol  |  Ritalinic acid  |  2-Aminoflubendazole-¹³C₆  |  AR-13324 M1 metabolite  |  16α-Hydroxyprednisolone-d₃  |  Lurasidone metabolite 14326 hydrochloride  |  Ilaprazole sulfone  |  Metoprolol EP impurity O-d₇ (hydrochloride)  |  N-Desmethyl Clomipramine-d₃ (hydrochloride)  |  1'-Hydroxymidazolam-¹³C₃  |  1-β-D-Glucosylsphingadienine (d18:2 (4E8E))

熱門產(chǎn)品線：重組蛋白  |  化合物庫  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標記物  |  寡核苷酸  |  抗體  |  點擊化學(xué)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫，我們致力于為全球科研客戶提供前沿的高品質(zhì)小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng)；
•   產(chǎn)品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產(chǎn)品，廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項目；
•   提供虛擬篩選，離子通道篩選，代謝組學(xué)分析檢測分析，藥物篩選等專業(yè)技術(shù)服務(wù)；
•   設(shè)有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告，確保產(chǎn)品的高純度、高品質(zhì)；
•   產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業(yè)團隊跟蹤最新的制藥及生命科學(xué)研究進展，為您提供全球新的活性化合物；
•   與世界各大制藥公司及著名科研機構(gòu)建立了長期的合作。